SEO URLwww.firestrike.ai/deals/amicus-therapeutics-biomarin-acquisition-2026-4
acquisitionAnnounced · Apr 27, 2026biotechSource · CredibleArticle · Factual
BioMarin acquires Amicus Therapeutics
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$4.8B
Target
Amicus Therapeutics
NASDAQ: FOLD · Princeton, New Jersey
Acquirer
BioMarin
Full Acquisition
Status
Pending
BioMarin agreed to acquire Amicus Therapeutics. Reported deal value: $4.8B. Status: Pending. Sector: biotech. Target headquarters context: Princeton, New Jersey, United States.
This page summarizes publicly available information about the transaction as of 2026-04-27. Figures and status may change as filings and press coverage update.
Forward-Looking Statements This press release contains forward-looking statements about, among other things, the business prospects of Amicus Therapeutics and BioMarin Pharmaceutical Inc. , including, without limitation, statements about: the prospective benefits of the acquisition
Deal timeline
Announced
Apr 27, 2026 · prnewswire.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotech with a reported deal value of $4.8B. Figures and status may change as sources update.
Sources: prnewswire.com · Primary article · FireStrike proprietary index